For example, NSCLC cells expressing the KRAS G12D mutation responded well to sorafenib while the G12V mutation was associated with resistance, suggesting that the different KRAS mutations interact differently with the treatment12. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.